Vetnuus | September 2025 17 Article This enhanced level of protection might be attributed to the synergistic effects of the inactivated virus conjugated to oxidised mannan, which may improve the vaccine’s ability to elicit stronger and more comprehensive immune responses.28 The Rab-OxMan vaccine was tested for local toxicity in SW1 mice and demonstrated to be safe at doses up to five times the therapeutic level 22 Certainly, future studies should also investigate the potential mechanisms behind the immune enhancements observed with the Rab-OxMan formulation in detail, including the role of innate immune pathways and specific immune cell types involved in the response. Furthermore, the implications of this research extend beyond rabies vaccination. The approach of utilising oxidised polysaccharides as adjuvants could be applicable to other veterinary and human vaccines, potentially leading to broader applications in vaccine development. Overall, these findings suggest that integrating oxidised mannan into rabies vaccine formulations presents a promising avenue for improving vaccination outcomes, enhancing public health responses to rabies, and potentially saving lives. In conclusion, this study presents compelling evidence that oxidised mannan can serve as a novel adjuvant or co-adjuvant for veterinary rabies vaccines. Significantly enhancing IgG production, modulating IgM responses, and increasing pro-inflammatory cytokine levels of the Rab-OxMan formulation demonstrate substantial improvements in immunogenicity and protective efficacy of the rabies vaccine. These findings suggest that incorporating oxidised mannan into rabies vaccine formulations could be a promising strategy for improving vaccination outcomes and enhancing public health efforts against rabies. Future studies should focus on further elucidating the mechanisms underlying these immune responses and evaluating the long-term efficacy of this novel vaccine formulation. v ACKNOWLEDGEMENTS The authors wish to acknowledge the Pasteur Institute of Iran for the financial support of the study (Project No. IR.PII.REC.1401.030). CONFLICT OF INTEREST STATEMENT None declared. Corresponding Author: Maryam Shahali Dept of Viral Vaccines Production, Research and Production Complex, Pasteur Institute of Iran, Tehran 3159915111, Iran Tel: +98-26-34916027 E-mail: maryam.shahali@gmail.com References available on request. “The South African Veterinary Association aims to serve its members and to further the status and image of the veterinarian. We are committed to upholding the highest professional and scientific standards by utilising the professional knowledge, skill and resources of our members, to foster close ties with the community and thus promote the health and welfare of animals and mankind”. MISSION STATEMENT SAVA-CVC supports vets that provide primary animal health care (vaccinations, deworming as well as tick and flea treatments, sterilisations) Servicing and enhancing the veterinary community since 1920! Tel: 012 346 1150 E-mail: vethouse@sava.co.za www.sava.co.za
RkJQdWJsaXNoZXIy OTc5MDU=